← Leaderboards
Joseph B Guarnaccia
Yale University
$172,675
Attributed
$172,675
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$172,675 · 6
By mechanism
M01$172,675 · 6
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Geetha Chalasani$4,543,503
- Jordan S Pober$30,894,969
- Insoo Kang$13,126,166
- Prabir Ray$20,599,877
- David M Rothstein$21,599,171
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchMultiple SclerosisDrug Screening /EvaluationHuman SubjectNervous System Disorder ChemotherapyHuman Therapy EvaluationPlacebosDrug Adverse EffectDosageInterferon BetaOutcomes ResearchClinical TrialsClinical Trial Phase IMagnetic Resonance ImagingPathologic ProcessImmunotherapySpinal Cord DisordersAntineoplasticsBrain StemChemopreventionCopolymerDisease /Disorder Proneness /RiskImmunopathology TherapyImmunoregulation
Grant awards (12)
MULTIPLE SCLEROSIS COPOLYMER 1 (COPAXONE)$0
M01 · FY2001 · RR
LEUSTATIN (CLADRIBINE) CLINICAL TRIAL IN CHRONIC PROGRESSIVE MS$0
M01 · FY2001 · RR
TRIAL OF INTERFERON BETA 1A IN TREATMENT OF SUBJECTS WITH HIGH RISK FOR MS$0
M01 · FY2001 · RR
TOLERABILITY OF AVONEX (INTERFERON BETA 1A) IN TREATMENT OF MULTIPLE SCLEROSIS$0
M01 · FY2001 · RR
EVALUATE EFFICACY OF AVONEX FOR MULTIPLE SCLEROSIS TREATMENT$0
M01 · FY2001 · RR
SAFETY/TOLERABILITY OF CGP 77116 IN MULTIPLE SCLEROSIS$0
M01 · FY2001 · RR
LEUSTATIN (CLADRIBINE) CLINICAL TRIAL IN CHRONIC PROGRESSIVE MS$34,535
M01 · FY2000 · RR
TRIAL OF INTERFERON BETA 1A IN TREATMENT OF SUBJECTS WITH HIGH RISK FOR MS$34,535
M01 · FY2000 · RR
TOLERABILITY OF AVONEX (INTERFERON BETA 1A) IN TREATMENT OF MULTIPLE SCLEROSIS$34,535
M01 · FY2000 · RR
EVALUATE EFFICACY OF AVONEX FOR MULTIPLE SCLEROSIS TREATMENT$34,535
M01 · FY2000 · RR
MULTIPLE SCLEROSIS COPOLYMER 1 (COPAXONE)$34,535
M01 · FY2000 · RR
SAFETY/TOLERABILITY OF CGP 77116 IN MULTIPLE SCLEROSIS$0
M01 · FY2000 · RR